BRCA-associated ovarian cancer (the experience of the Chemotherapy Department in N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of Russia)


Cite item

Full Text

Abstract

In recent years, the main scientific directions concerning ovarian cancer have been associated with the attempt to individualize the treatment based on prognostic and predictive molecular biological markers. The damage in BRCA1 and BRCA2 genes is identified in 10-15% of ovarian cancer cases. The main function of BRCA proteins is responsibility for repairing double-strand break in DNA by a mechanism of homologous recombination. The result of BRCA gene dysfunction is BRCA-associated DNA damage repair mechanism. As a result, these tumors can be extremely sensitive to DNA-damaging cytostatic agents - such as platinum-based drugs. Several studies show the better survival rates of patients with BRCA mutations in comparison with sporadic ovarian cancer. The information concerning the course of disease and treatment characteristics of patients with ovarian cancer associated with BRCA1, 2 mutations in the Russian population of patients is extremely limited.

About the authors

S V Khokhlova

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

Email: SVKhokhlova@mail.ru
д-р мед. наук, ст. науч. сотр. отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

V A Gorbunova

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зав. отд-нием химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

L N Lyubchenko

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

д-р мед. наук, рук. лаб. клин. онкогенетики ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

E N Imyanitov

N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., рук. лаб. молекулярной онкологии ФГБУ НИИО им. Н.Н.Петрова 197758, Russian Federation, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68

References

  1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Вестн. Российского онкологического научного центра им. Н.Н.Блохина РАМН. 2013; 22 (3): 9-142.
  2. Имянитов Е.Н. Общие представления о наследственных опухолевых синдромах. Практическая онкология. 2014; 15 (3): 101.
  3. Максимов С.Я., Имянитов Е.Н. и др. Клинические особенности BRCA-позитивного рака яичников. Сиб. онкологический журн. 2013; 6 (60).
  4. Мамедов В.А., Бахидзе Е.В., Имянитов Е.Н. Оценка эффективности лекарственного лечения у больных раком яичников с различным статусом гена BRCA. Сиб. онкологический журн. 2009; S1: 129-30.
  5. Смирнова Т.Ю., Поспехова Н.И., Любченко Л.Н. и др. Высокая частота мутаций в генах BRCA1 и BRCA2 при раке. Бюлл. эксперимент. биологии и медицины. 2007; 144 (7): 93-5.
  6. Fedorova O.E, Liubchenko L.N, Paiadini Iu.G et al. Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and priary multiple tumors involving the ovaries. Patients of Russian population using biochips. Mol Biol (Mosk) 2007; 41: 37.
  7. Imyanitov E.N, Byrski T. Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract 2013; 11 (1): 2. doi: 10.1186/1897-4287-11-2.
  8. Imyanitov E.N. Ovarian cancer genome. Methods Mol Biol 2013; 1049: 3-7.
  9. Imyanitov E.N, Moiseyenko V.M. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011; 9 (1): 5. doi: 10.1186/1897-4287-9-5.
  10. Armstrong D.K et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New En J Med 2006; 354 (1): 34-43.
  11. Bolton K, Chenevix-Trench G et al. Association between BRCA1 and BRCA2 Mutations and Survival in women with Invasive Epithelial Ovarian Cancer. JAMA 2012; 307 (4): 382-90.
  12. Boyd J, Sonoda Y, Federici M.G et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283 (17): 2260-5.
  13. Cass I, Baldwin R et al. Improved Survival in women with BRCA-associated Ovarian carcinoma. Am Cancer Soc 2003; 97 (9).
  14. Chan J.K, Tian C, Monk B.J et al. Prognostic factors for high - risk early - stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 2008; 112 (10: 2202-10.
  15. Deng C.X, Brodie S.G. Role of BRCA 1 and its interacting proteins. Bioessays 2010; 22 (8): 728-37.
  16. Farmer H, Mc Cabe N, Lord C.J et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434 (7035): 917-21.
  17. Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int 2013; c. 928562.
  18. Lesnock J.L et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer 2013; 108 (6): 1231-7.
  19. Leunen K et al. Does paclitaxel - carboplatin chemotherapy in a dose - dense regimen enhance survival of BRCA-related ovarian cancer patients? Intl J Gynecologic Cancer 2009; 19 (9): 1501-4.
  20. Parvin J.D. BRCA 1 at a branch point. Proc Natl Acad Dci USA 2001; 98 (11): 5952-4.
  21. Rubin S.C, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ - line mutations of BRCA1. N Engl J Med 1996; 335 (19): 1413-6.
  22. Safra T, Rogowski O, Muggia F.M. The effect of germ - line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int J Gynecologic Cancer 2014; 24 (3): 488-95.
  23. Yang D. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306 (14): 1557-65.
  24. Yang D, Khan S, Sun Y et al. Association between BRCA2 but not BRCA1 mutations and beneficial Survival, Chemotherapy sensitivy, and gene Mutator Phenotype in Patients with ovarian cancer. JAMA 2011; 306 (14): 1557-65.
  25. Zhong Q, Peng H et al. Effects of BRCA1-and BRCA2-related Mutations on Ovarian and Breast Cancer Survival: A Meta - analysis. Clin Cancer Res 2014; 21 (1): 211-20.
  26. Ashworth A et al. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double - strand break repair. J Clin Oncol 2008; 26: 3785-90.
  27. Mc Cabe N, Turner N.C, Lord C.J et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to Poly(ADP-Ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-15.
  28. Audeh M.W et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof - of - concept trial. Lancet 2010; 376: 245-51.
  29. Ledermann J, Harter P. Olaparib maintenance therapy in patients with platinum - sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancel. Published Online May 30, 2014 http://dx.doi.org/10.1016/ S1470-2045(14)70228-1

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies